Drug Development

Articles

Kindeva Drug Delivery plans capital investment and jobs growth.

Former 3M Drug Delivery Systems Launches as Kindeva Drug Delivery

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

In light of the hype around chloroquine and hydroxychloroquine as potential COVID-19 treatments, it is important to remember that drug repurposing should never be rushed, irrespective of the urgency of the situation.

Can We Teach an Old Drug New Tricks?

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Equipment and process optimization must be considered for scaling up these developmental technologies to commercial production.

Manufacturing Microneedle Array Patches for Vaccine Delivery

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Formulating an ADC Development Solution

Agnes Shanley is senior editor of Pharmaceutical Technology.

Discovery of carcinogenic nitrosamines in three of the world’s most widely prescribed drugs is driving efforts to better detect, control and prevent their generation in APIs and finished drug products.


Contamination Drives a More Concerted Approach to Genotoxins

Reformulation strategies can provide drug developers with a head start to achieve promising options that benefit the patient.


A Welcome Change: The Benefits of Reformulation

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.

Lonza, Moderna Form Global Collaboration to Manufacture Moderna’s COVID-19 Vaccine

AstraZeneca and the University of Oxford have announced that they will collaborate on the global development and distribution of the university’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection.

AstraZeneca, University of Oxford Collaborate on COVID-19 Vaccine

Merck will provide funding and will work with researchers at the Institute for Systems Biology to identify targets for therapeutic intervention and vaccine development.

Formulation and Drug Delivery